Transition of visual acuity before initial treatment with neovascular age-related macular degeneration over the past years (A multicenter retrospective study)
Not Applicable
- Conditions
- neovascular age-related macular degeneration
- Registration Number
- JPRN-UMIN000029497
- Lead Sponsor
- Department of Ophthalmology, Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3096
Inclusion Criteria
Not provided
Exclusion Criteria
Patients have received photodynamic therapy or intravitreal injections of ranibizumab, aflibercept, pegaptanib, or bevacizumab before receiving the initial treatment at each hospital, or patients who refused to participate this study, or patients who are judged to be unfit as the participants of this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual acuity before initial treatment
- Secondary Outcome Measures
Name Time Method Type of initial treatment Visual acuity one year and 2 years after the initial treatment Central subfield retinal thickness before initial treatment, one year and 2 years after the initial treatment